Format

Send to

Choose Destination
See comment in PubMed Commons below
J Allergy Clin Immunol. 2016 Mar;137(3):710-7. doi: 10.1016/j.jaci.2015.09.057. Epub 2015 Dec 22.

Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β2-agonist regulation from 2005-2011.

Author information

  • 1Center for Clinical and Outcomes Research, Kaiser Permanente Georgia, Atlanta, Ga; Evidence Space, Hamilton, Bermuda.
  • 2Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
  • 3Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass.
  • 4Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
  • 5Department of Medicine and Biostatistics, Vanderbilt University School of Medicine, Nashville, Tenn.
  • 6Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
  • 7Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Mass; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Mass. Electronic address: meghan_baker@harvardpilgrim.org.

Abstract

BACKGROUND:

Safety concerns associated with long-acting β2-agonists (LABAs) have led to many US Food and Drug Administration (FDA) regulatory activities for this class of drugs. Little is known about the effect of these regulatory activities on use of LABA-containing agents or other asthma medications.

METHODS:

We created rolling cohorts of pediatric and adult asthmatic patients in the Mini-Sentinel Distributed Database between January 2005 and June 2011. The proportions of asthmatic patients using LABA-containing products, inhaled corticosteroids (ICSs), leukotriene modifiers, short-acting β2-agonists, oral corticosteroids, other bronchodilators, and no medications were measured on a monthly basis, and the changes were evaluated by using interrupted time series with segmented regression analysis.

RESULTS:

When the 2005 regulatory activity was announced, there were statistically significant decreases in the use of fixed-dose ICS-LABA agents in children (-0.98 percentage points) and adults (-1.24 percentage points). Increased use of ICSs and leukotriene modifiers was observed just after the regulatory activities were announced in both children and adults. Although of smaller magnitude, continued favorable changes in the use of LABA agents were observed after the 2010 FDA regulatory activity.

CONCLUSION:

The 2005 and 2010 FDA regulatory activities might have contributed to reduced use of LABA agents, as intended; however, their effect, independent of other factors, cannot be determined. Use of other classes of asthma medications was similarly affected.

KEYWORDS:

Long-acting β(2)-agonist; US Food and Drug Administration; asthma; drug safety; medication use

PMID:
26725997
DOI:
10.1016/j.jaci.2015.09.057
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center